Aegis Boosts PT on Catalyst Pharma (CPRX) to $5.50; Thinks Firdapse Competition Overstated
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Stocks face worst month since September, yen swings after BoJ
- Microsoft fiscal Q3 results top estimates as AI revolution spurs cloud growth
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
- Oil prices on track to snap two-week losing streak
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Catalyst Pharmaceutical (CPRX) Drops Pre-Market
October 18, 2013 9:20 AM EDTCatalyst Pharmaceutical (Nasdaq: CPRX) stock declined pre-market on Friday. The move may be tied to an article by Adam Feuerstein in The Street.... More
DMC Recommends Catalyst Pharma (CPRX) Continue Firdapse Phase III
October 15, 2013 11:52 AM EDTCatalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) announced that, at a recently held meeting, the independent Data Monitoring Committee (DMC) overseeing the Company's ongoing pivotal Phase III clinical trial in the United States and Europe evaluating Firdapse for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) recommended that the Company... More
